 was published by the European Medicines Agency on 17 July 2025){kind=link}
The updated composition of the Emergency Task Force (ETF) was published by the European Medicines Agency on 17 July 2025. Established under regulation (EU) 2022/123, the ETF is responsible for managing preparedness for public health emergencies. The new composition of the ETF reflects the expertise required to prepare for potential future public health emergencies of biological origin based on past experience. Additional ad hoc experts may be appointed as required in relation to other potential threats of chemical, nuclear or radiation origin.
The ETF is co-chaired by Marco Cavalieri, a staff member of the EMA appointed by the Agency’s Executive Director, and Bruno Sepodes, the Chair of the Committee for Human Medicinal Products (CHMP). The Task Force also includes the Chairs of the Pharmacovigilance Risk Assessment Committee (PRAC) and of the Paediatric Committee (PDCO), as well as representatives from several of the EMA’s committees and Working Parties. The ETF is completed by three EMA staff members, one representative each from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) and the Clinical Trials Coordination and Advisory Group (CTAG), and two clinical trial experts proposed by the Clinical Trials Coordination Group (CTCG).